Clinical Trial Update: Usefulness of Blood Biomarkers for Overall Survival in NSCLC

View source ↗

Summary

The study evaluates whether blood-based biomarkers can predict overall survival in non-small cell lung cancer. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Maastricht Radiation Oncology | Conditions: Non-small Cell Lung Cancer | Status: COMPLETED